But for every patient the clock is ticking, as children are only eligible if they have enough growth ahead of them for the technology to make a difference. And all too often, insurance companies can delay the treatment so long that patients are no longer eligible if and when insurers approve the procedure.
ZimVie SVP and Global Spine President Rebecca Whitney spoke about the system’s development and commercialization with ZimVie Spine Global R&D Director Ryan Watson today at DeviceTalks Boston.